Schedule 13G ownership disclosure
Apogee Therapeutics Inc
Common Stock · CUSIP: 03770N101
Event date: 2025-12-31
- Filing-level shares
- 2,857,824
- Percent of class
- 5.21%
- The Vanguard Group
Shares: 2,857,824 · Class: 5.21%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000102909-26-000084
- Form type
- SCHEDULE 13G
- Filer
- Apogee Therapeutics, Inc.
- CIK
- CIK 1974640
- Filed
- Jan 30, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership